论文部分内容阅读
目的探究二甲双胍治疗糖耐量降低的临床效果及其作用机制。方法确诊为糖耐量降低的患者70例,随机分为二甲双胍组与对照组,各35例。指导对照组患者健康宣教、控制饮食及运动干预治疗等干预治疗方法 ,二甲双胍组患者在对照组基础上口服二甲双胍治疗。两组患者接受治疗时间均为12个月。观察两组患者治疗后的体质量指数、空腹血糖及餐后2 h血糖变化情况,并与治疗前比较;同时观察两组患者新发糖尿病情况并进行比较。结果治疗12个月后二甲双胍组患者体质量指数(20.12±2.63)kg/m2、空腹血糖(5.11±0.81)mmol/L、餐后2 h血糖(7.66±1.12)mmol/L均明显优于治疗前水平,差异具有统计学意义(P<0.05);对照组患者治疗前后体质量指数、空腹血糖及餐后2 h血糖对比差异无统计学意义(P>0.05)。治疗后二甲双胍组无新发糖尿病患者,对照组有7例新发糖尿病患者,差异具有统计学意义(P<0.05)。结论二甲双胍应用于糖耐量降低的治疗取得了良好的效果,同时还能够有效的预防或者延缓糖尿病的发生,值得临床推广。
Objective To investigate the clinical effect and mechanism of metformin in the treatment of impaired glucose tolerance. Methods 70 cases of patients with impaired glucose tolerance were randomly divided into metformin group and control group, 35 cases in each group. Guidance control group of patients health education, diet and exercise intervention treatment intervention therapy, metformin patients in the control group on the basis of oral metformin treatment. Both groups received treatment for 12 months. After treatment, body mass index, fasting blood glucose and postprandial blood glucose at 2h after treatment were observed and compared with those before treatment. The incidence of new-onset diabetes in both groups were also observed and compared. Results The body mass index (20.12 ± 2.63) kg / m2, fasting blood glucose (5.11 ± 0.81) mmol / L, and postprandial blood glucose (2 7.66 ± 1.12) mmol / L were significantly better in the metformin group after 12 months of treatment (P <0.05). There was no significant difference in body mass index, fasting blood glucose and 2 h postprandial blood glucose before and after treatment in the control group (P> 0.05). There was no new-onset diabetes in the metformin group after treatment. There were 7 cases of new-onset diabetes in the control group, the difference was statistically significant (P <0.05). Conclusion Metformin used in the treatment of impaired glucose tolerance has achieved good results, but also can effectively prevent or delay the occurrence of diabetes, it is worth clinical promotion.